The founding idea of a startup isn’t always the one that sticks. In the case of Madison-based Plumb Pharmaceuticals, the original intent was to develop a long-term pain management treatment for animals.
About 10 years later, Plumb is now looking at federal Food and Drug Administration approval for a drug delivery method that will help humans battling opioid addiction.
Founders Timothy Heath and Lisa Krugner-Higby have created a formula of liposomes that, when loaded with medication and injected under the skin, slowly releases medications. Plumb is currently loading the liposomes with naltrexone or buprenorphine — which curb cravings and block opioid receptors — but Heath and Krugner-Higby believe other medications, such as those for mental health conditions, can also be delivered through this process.
Liposomes have been used for extended-release drugs for years, Heath said, but the release span for those currently on the market is typically a month. Plumb’s patented method, called Advanced Quantload Technology, has been shown in animal tests to extend that release time to three months. Click here to read the full article.